Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas

Cancer

Volumn 116, Issue 17, 2010, Pages 3988-3999

  Chamberlain, Marc C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiangiogenesis; Bevacizumab; Glioblastoma; Glioma; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; FOTEMUSTINE; IRINOTECAN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC THERAPY; BLEEDING; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HUMAN; HYPERTENSION; LEUKOENCEPHALOPATHY; MONOTHERAPY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SINGLE DRUG DOSE; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); GLIOMA; RECURRENT DISEASE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; RECURRENCE; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77956822655     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25256     Document Type: Review

References (97)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Prados MD, Seiferheld W, Sandler HM, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 2004;58:1147-1152.
3. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine and vincristine improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-2722.
4. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
5. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762-2771.
6. Ballman KV, Buckner JC, Brown PD, et al. The relationship between 6-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9:29-38.
7. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10:162-170.
8. National Comprehensive Cancer Network (NCCN). NCCN Practice Guidelines in Oncology: Central Nervous System Cancers, volume 1. 2008. Fort Washington, Pa: National Comprehensive Cancer Network; 2009. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/cns.pdf. Accessed May 21, 2009.
9. Genentech, Inc. Avastin [package insert]. South San Francisco, Calif: Genentech, Inc.; 2009.
10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
11. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69(suppl 3):11-16.
12. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst. 1972;48:347-356.
13. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat Rev Neurosci. 2007;8:610-622.
14. Salmaggi A, Eoli M, Frigerio S, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol. 2003;62:297-303.
15. Pore N, Liu S, Haas-Kogan DA, O'Rourke DM, Maity A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res. 2003;63:236-241.
16. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol. 2005;7:134-153.
17. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996;77:362-372.
18. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer. 1999;84:10-18.
19. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003;9:3369-3375.
20. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas [abstract]. J Clin Oncol. 2009;27(suppl 15):98s. Abstract 2045.
21. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18:708-715.
22. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;60:353-357.
23. Brem S, Grossman SA, Carson KA, et al. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol. 2005;7:246-253.
24. Mikkelsen T, Lush R, Grossman SA, et al. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest New Drugs. 2007;25:259-263.
25. Drappatz J, Wong ET, Schiff D, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73:222-227.
26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
27. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
28. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
29. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
30. Rohr UP, Augustus S, Lasserre SF, Compton P, Huang J. Safety of bevacizumab in patients with metastases to the central nervous system [abstract]. J Clin Oncol. 2009;27(suppl 15):88s. Abstract 2007.
31. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Neuro Oncol. 2005;7:369. Abstract 342.
32. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259.
33. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729. (Pubitemid 350086473)
34. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
35. Desjardins A, Reardon DA, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008;14:7068-7073.
36. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-745.
37. Gilbert MR, Wang M, Aldape K, et al. RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM) [abstract]. J Clin Oncol. 2009;27(suppl 15):89s. Abstract 2011.
38. Bao S, Wu Q, McLendon R, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-760.
39. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69-82.
40. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731-3736.
41. Winkler F, Kozin SV, Tong R, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation angiopoietin-1 and matrix metalloproteinases. Cancer Cell. 2004;6:553-563.
42. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
43. Gorski DH, Beckert MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374-3378.
44. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008;8:541-553.
45. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258-1260.
46. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779-787.
47. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72:1217-1222.
48. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75:156-163.
49. Chamberlain MC, Johnston S. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol. 2010;96:259-269.
50. Raizer JJ, Grimm S, Rice L, et al. A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas [abstract]. J Clin Oncol. 2009;27(suppl 15):98s. Abstract 2044.
51. Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol. 2009;91:359-367.
52. Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009;115:1734-1743.
53. Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol. 2008;26:1012-1013.
54. Wakai S, Yamakawa K, Manaka S, Takakura K. Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery. 1982;10:437-444.
55. Schrader B, Barth H, Lang EW, et al. Spontaneous intracranial haematomas caused by neoplasms. Acta Neurochir (Wien). 2000;142:979-985.
56. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106:601-608.
57. Raizer JJ, Gallot L, Cohn R, et al. A phase II safety study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas [abstract]. J Clin Oncol. 2007;25(suppl 15):106s. Abstract 2079.
58. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008;112:2267-2273.
59. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516-1525.
60. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol. 2002;56:183-188.
61. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 2003;97:2381-2386.
62. Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004;6:21-27.
63. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006;8:189-193. (Pubitemid 46542664)
64. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;101:1986-1994.
65. Soffietti R, Ruda R, Trevisan E, et al. Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: a multicenter Italian study [abstract]. J Clin Oncol. 2009;27(suppl 15):90s. Abstract 2012.
66. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;10:355-360.
67. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
68. Wong ET, Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol. 2007;25:4705-4706.
69. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer. 2003;89:8-14.
70. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26:271-278.
71. 18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623-2630.
72. Chinot OL, Bourdouresque F, Bequet C, et al. Correlation of serum urokinase plasminogen activator (uPA) to progression of recurrent malignant glioma during bevacizumab treatment: a marker of invasive phenotype and a candidate to monitor therapy [abstract]. J Clin Oncol.;2009:27(suppl 15):101s. Abstract 2059.
73. Paldino M, Desjardins A, Friedman HS, Vredenburgh JJ, Barboriak DP. Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab [abstract]. J Clin Oncol. 2009;27(suppl 15):101s. Abstract 2058.
74. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007;67:323-326.
75. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994;44:675-680.
76. Wick W, Kuker W. Brain edema in neurooncology: radiological assessment and management. Onkologie. 2004;27:261-266.
77. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293:557-564. (Pubitemid 40171237)
78. Potthast L, Chowdhary S, Pan E, Yu D, Zhu W, Brem S. The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab [abstract]. J Clin Oncol. 2009;27(suppl 15):101s. Abstract 2057.
79. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
80. Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol. 2008;21:736-744.
81. Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009;11:550-555.
82. Stankewitz S, Dresemann G. Addition of continuous low dose temozolomide (T) to bevacizumab (Bev) plus irinotecan (Iri) after bevacizumab plus irinotecan failure in heavily pretreated glioblastoma multiforme (GBM) [abstract]. J Clin Oncol. 2009;27(suppl 15). Abstract e13015.
83. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7:1152-1160.
84. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71:1372-1380.
85. Narayana A, Golfinos JG, Fischer I, et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys. 2008;72:383-389.
86. Gruber ML, Raza S, Gruber D, Narayana A. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity [abstract]. J Clin Oncol. 2009;27(suppl 15):91s. Abstract 2017.
87. Lai A, Nghiemphu P, Green R, et al. Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme [abstract]. J Clin Oncol. 2009;27(suppl 15):87s. Abstract 2000.
88. Nicholas MK, Lucas RV, Arzbaecher J, et al. Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: preliminary results of a phase II study [abstract]. J Clin Oncol. 2009;27(suppl 15):91s. Abstract 2016.
89. Vredenburgh JJ, Desjardins A, Reardon DA, et al. Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM) [abstract]. J Clin Oncol. 2009;27(suppl 15):90s. Abstract 2015.
90. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81-83.
91. Wong ET, Huberman M, Lu XQ, Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol. 2008;26:5649-5650.
92. Torcuator R, Zuniga R, Mohan YS, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol. 2009;94:63-68.
93. Green RM, Cloughesy TF, Stupp R, et al. Bevacizumab for recurrent ependymoma. Neurology. 2009;73:1677-1680.
94. Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009;72:1601-1666.
95. Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors [abstract]. J Clin Oncol. 2009;27(suppl 15):100s. Abstract 2054.
96. Plotkin S, Halpin C, Stemmer-Rachamimov A, et al. Activity of bevacizumab against NF2-related vestibular schwannomas [abstract]. Neuro Oncol. 2008;10:759-915. Abstract ET-51.
97. Greenberg BM, Blakeley JO. Bevacizumab for the treatment of radiation myelopathy [abstract]. Neurology. 2009;72:11. Abstract A30.